

2019 Future of Atrial Fibrillation R&D Pipeline Drugs and Companies- Analysis of Global Atrial Fibrillation Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/279F46C075DEN.html>

Date: January 2019

Pages: 85

Price: US\$ 2,199.00 (Single User License)

ID: 279F46C075DEN

Abstracts

The global demand for Atrial Fibrillation treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Atrial Fibrillation pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Atrial Fibrillation pipeline companies from advancing their products into Phase 3 or Phase 4.

Atrial Fibrillation Report Description

The H1 2019 pipeline review report on Atrial Fibrillation pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Atrial Fibrillation pipeline compounds.

The Atrial Fibrillation pipeline guide presents information on all active drugs currently being developed for Atrial Fibrillation. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Atrial Fibrillation pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Atrial Fibrillation drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Atrial Fibrillation product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Atrial Fibrillation pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Atrial Fibrillation pipeline report includes

An overview of Atrial Fibrillation disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Atrial Fibrillation pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Atrial Fibrillation pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Atrial Fibrillation pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL ATRIAL FIBRILLATION PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Atrial Fibrillation Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Atrial Fibrillation pipeline, H1- 2019
- 3.5 Mechanism of Action wise Atrial Fibrillation Pipeline Candidates

4. ACESION PHARMA ATRIAL FIBRILLATION PIPELINE DETAILS

- 4.1 Acesion Pharma Business Profile
- 4.2 Acesion Pharma Atrial Fibrillation Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. AETAS PHARMA ATRIAL FIBRILLATION PIPELINE DETAILS

- 5.1 Aetas Pharma Business Profile
- 5.2 Aetas Pharma Atrial Fibrillation Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. ALLOSTEROS THERAPEUTICS INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 6.1 Allosteros Therapeutics Inc Business Profile
- 6.2 Allosteros Therapeutics Inc Atrial Fibrillation Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. ANABIOS CORPORATION ATRIAL FIBRILLATION PIPELINE DETAILS

- 7.1 AnaBios Corporation Business Profile
- 7.2 AnaBios Corporation Atrial Fibrillation Drug Details
 - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. ARCA BIOPHARMA INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 8.1 ARCA biopharma Inc Business Profile
- 8.2 ARCA biopharma Inc Atrial Fibrillation Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. BOSTON PHARMACEUTICALS INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 9.1 Boston Pharmaceuticals Inc Business Profile
- 9.2 Boston Pharmaceuticals Inc Atrial Fibrillation Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. CORREVIO PHARMA CORP. ATRIAL FIBRILLATION PIPELINE DETAILS

- 10.1 Correvio Pharma Corp. Business Profile
- 10.2 Correvio Pharma Corp. Atrial Fibrillation Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. DAIICHI SANKYO CO LTD ATRIAL FIBRILLATION PIPELINE DETAILS

- 11.1 Daiichi Sankyo Co Ltd Business Profile
- 11.2 Daiichi Sankyo Co Ltd Atrial Fibrillation Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. DONG-A SOCIO HOLDINGS CO LTD ATRIAL FIBRILLATION PIPELINE DETAILS

12.1 Dong-A Socio Holdings Co Ltd Business Profile

12.2 Dong-A Socio Holdings Co Ltd Atrial Fibrillation Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. EDGE THERAPEUTICS INC ATRIAL FIBRILLATION PIPELINE DETAILS

13.1 Edge Therapeutics Inc Business Profile

13.2 Edge Therapeutics Inc Atrial Fibrillation Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. ESPERO BIOPHARMA INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 14.1 Espero BioPharma Inc Business Profile
- 14.2 Espero BioPharma Inc Atrial Fibrillation Drug Details
 - 14.2.1 Drug Snapshot
 - 14.2.1.1 Originator
 - 14.2.1.2 Collaborator/Co-Developer
 - 14.2.1.3 Route of Administration
 - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 14.2.1.5 Area
 - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15. G3 PHARMACEUTICALS INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 15.1 G3 Pharmaceuticals Inc Business Profile
- 15.2 G3 Pharmaceuticals Inc Atrial Fibrillation Drug Details
 - 15.2.1 Drug Snapshot
 - 15.2.1.1 Originator
 - 15.2.1.2 Collaborator/Co-Developer
 - 15.2.1.3 Route of Administration
 - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 15.2.1.5 Area
 - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16. GILEAD SCIENCES INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 16.1 Gilead Sciences Inc Business Profile
- 16.2 Gilead Sciences Inc Atrial Fibrillation Drug Details
 - 16.2.1 Drug Snapshot
 - 16.2.1.1 Originator
 - 16.2.1.2 Collaborator/Co-Developer

- 16.2.1.3 Route of Administration
- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. HUYA BIOSCIENCE INTERNATIONAL ATRIAL FIBRILLATION PIPELINE DETAILS

- 17.1 HUYA Bioscience International Business Profile
- 17.2 HUYA Bioscience International Atrial Fibrillation Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. INCARDA THERAPEUTICS INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 18.1 InCarda Therapeutics Inc Business Profile
- 18.2 InCarda Therapeutics Inc Atrial Fibrillation Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity

- 18.3 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. MERCK & CO INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 19.1 Merck & Co Inc Business Profile
- 19.2 Merck & Co Inc Atrial Fibrillation Drug Details
 - 19.2.1 Drug Snapshot
 - 19.2.1.1 Originator
 - 19.2.1.2 Collaborator/Co-Developer
 - 19.2.1.3 Route of Administration
 - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 19.2.1.5 Area
 - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20. N-GENE RESEARCH LABORATORIES INC ATRIAL FIBRILLATION PIPELINE DETAILS

- 20.1 N-Gene Research Laboratories Inc Business Profile
- 20.2 N-Gene Research Laboratories Inc Atrial Fibrillation Drug Details
 - 20.2.1 Drug Snapshot
 - 20.2.1.1 Originator
 - 20.2.1.2 Collaborator/Co-Developer
 - 20.2.1.3 Route of Administration
 - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 20.2.1.5 Area
 - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details

20.7 Latest Drug Developments

21. NISSAN CHEMICAL INDUSTRIES LTD ATRIAL FIBRILLATION PIPELINE DETAILS

21.1 Nissan Chemical Industries Ltd Business Profile

21.2 Nissan Chemical Industries Ltd Atrial Fibrillation Drug Details

21.2.1 Drug Snapshot

21.2.1.1 Originator

21.2.1.2 Collaborator/Co-Developer

21.2.1.3 Route of Administration

21.2.1.4 Orphan Drug/Fast Track/Special Designation

21.2.1.5 Area

21.2.1.6 Type of Molecular Entity

21.3 Current Status

21.4 Drug Overview

21.5 Drug Mechanism of Action

21.6 Clinical/Pre-clinical Trial Details

21.7 Latest Drug Developments

22. OMEICOS THERAPEUTICS GMBH ATRIAL FIBRILLATION PIPELINE DETAILS

22.1 OMEICOS Therapeutics GmbH Business Profile

22.2 OMEICOS Therapeutics GmbH Atrial Fibrillation Drug Details

22.2.1 Drug Snapshot

22.2.1.1 Originator

22.2.1.2 Collaborator/Co-Developer

22.2.1.3 Route of Administration

22.2.1.4 Orphan Drug/Fast Track/Special Designation

22.2.1.5 Area

22.2.1.6 Type of Molecular Entity

22.3 Current Status

22.4 Drug Overview

22.5 Drug Mechanism of Action

22.6 Clinical/Pre-clinical Trial Details

22.7 Latest Drug Developments

23. THE GENEVA BIOTECH CENTER SA ATRIAL FIBRILLATION PIPELINE DETAILS

- 23.1 The Geneva Biotech Center SA Business Profile
- 23.2 The Geneva Biotech Center SA Atrial Fibrillation Drug Details
 - 23.2.1 Drug Snapshot
 - 23.2.1.1 Originator
 - 23.2.1.2 Collaborator/Co-Developer
 - 23.2.1.3 Route of Administration
 - 23.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 23.2.1.5 Area
 - 23.2.1.6 Type of Molecular Entity
- 23.3 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24. VERSEON CORP ATRIAL FIBRILLATION PIPELINE DETAILS

- 24.1 Verseon Corp Business Profile
- 24.2 Verseon Corp Atrial Fibrillation Drug Details
 - 24.2.1 Drug Snapshot
 - 24.2.1.1 Originator
 - 24.2.1.2 Collaborator/Co-Developer
 - 24.2.1.3 Route of Administration
 - 24.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 24.2.1.5 Area
 - 24.2.1.6 Type of Molecular Entity
- 24.3 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

20. LATEST ATRIAL FIBRILLATION DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology

21.3 Contact Information

I would like to order

Product name: 2019 Future of Atrial Fibrillation R&D Pipeline Drugs and Companies- Analysis of Global Atrial Fibrillation Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/279F46C075DEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/279F46C075DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970